Leading the era of AI changes, Insilico Medicine is proudly listed in fortune 50 AI innovators - EurekAlert
Insilico Medicine receives IND clearance from FDA for ISM5939, an oral ENPP1 inhibitor treating solid tumors - EurekAlert
Insilico Medicine announces Pharma.AI week we - EurekAlert
Insilico Medicine announces positive topline - EurekAlert
Insilico Medicine enters into revolving loan facility of up to US$100 Million with HSBC - EurekAlert
Insilico Medicine achieves a milestone in AI-facilitated drug discovery collaboration with Sanofi - EurekAlert
Insilico Medicine appoints Carol Satler, MD. - EurekAlert
Insilico Medicine reports positive Phase IIa results for ISM001-055, a novel first-in-class drug treatment for idiopathic pulmonary fibrosis (IPF) designed using generative AI - EurekAlert
Insilico Medicine received IND approval and o - EurekAlert
Insilico Medicine introduces Science42: DORA, the intelligent writing assistant for accelerated research - EurekAlert
Insilico Medicine leadership team shares insights on AI-powered healthcare innovation at 2024 Summer Davos - EurekAlert
Insilico Medicine completes patient enrollment in its Phase IIa Study in China investigating INS018_055 for Idiopathic ... - EurekAlert
Insilico Medicine nominates the winner of documentary hackathon to raise awareness of AI drug discovery through ... - EurekAlert
Insilico Medicine receives Health Innovation Trailblazer Award: Industry from UAE Genetic Diseases Association - EurekAlert
Insilico Medicine President Alex Aliper, Ph.D. to present at Systems Aging Gordon Research Conference - EurekAlert
Insilico Medicine leadership presents on key issues in AI drug discovery at BIO International - EurekAlert
Insilico Medicine introduces nach0: A one-stop LLM for chemical and biomedical tasks - EurekAlert
Insilico Medicine moves its headquarters to Boston - EurekAlert
Insilico Medicine receives IND approval from FDA for novel MAT2A inhibitor ISM3412 - EurekAlert
Using generative AI, Insilico Medicine discovers new class of Polθ Inhibitors for BRCA-deficient cancers - EurekAlert
